152
Registered trials
77
Recruiting
56
Completed trials
82
Sponsors
23
Countries
Phase III:
64
Phase II/III:
11
Phase II:
53
Phase I/II:
11
Phase III/IV:
3
Phase IV:
8
Phase I (Other):
1
Phase I (FiH):
1
Oversight events:
6 serious breaches
11 temporary halts
1 urgent safety measure
8 unexpected events
1 corrective measure
across 18 trials
View oversight register →
Indications tested
Triple negative breast cancer
9
Breast cancer
6
Gastric cancer
4
Colorectal cancer metastatic
4
Colorectal cancer
4
Colorectal cancer stage III
4
Colorectal cancer stage II
3
Metastatic gastric cancer
3
Breast cancer metastatic
3
HER2 positive breast cancer
3
Hormone receptor positive HER2 negative breast cancer
3
Rectal cancer
3
Sponsors using this IMP
Merck Sharp & Dohme LLC
13
AstraZeneca AB
11
Unicancer
8
Fondation Franc.Cancerologie Digestive
6
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
6
IRCCS Istituto Nazionale Tumori Fondazione Pascale
6
Fondazione GONO G.I.
5
Bristol-Myers Squibb Services Unlimited Company
4
Centre Hospitalier Universitaire Rouen
4
HUS-Yhtymae
3
Amsterdam UMC
2
Amsterdam UMC Stichting
2
All trials — page 7
152 total-
CIRCULATE Ended
Showing 145–152 of 152 trials